Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection

NCT03244644 is registered in ClinicalTrials.gov with Rebiotix Inc. as lead sponsor.

NCT NCT03244644
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03244644 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile Infection
Lead sponsor
Rebiotix Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2017
Completion date
August 3, 2020
Enrollment
320 (actual)
Sites
66

Conditions

As the registry lists them; a condition with its own page is linked.

clostridium difficile infection (cdi)